AMY HARRUP: Open Payments
NPI 1033798665 · SOUTH HILL, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$753 in 39 payments from 14 companies in 2025. Trend: 2023 $444 · 2024 $642 · 2025 $753
Food & beverage: $753
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $210 |
| ABBVIE INC. | 6 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $85 |
| AstraZeneca Pharmaceuticals LP | 5 | $78 |
| Averitas Pharma Inc. | 2 | $54 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| Dexcom, Inc. | 1 | $38 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Amgen Inc. | 1 | $20 |
Products named: Ozempic, VRAYLAR, CAPLYTA, QUTENZA, BREZTRI, FANAPT, XIFAXAN, Dexcom G6 Transmitter.
Industry payments across VA — which companies pay providers there.
